NCI Cohort Consortium

Contents

NCI Cohort Consortium

The NCI Cohort Consortium is a collaborative network of prospective cohort studies convened by the National Cancer Institute to accelerate research on cancer etiology, prevention, and survivorship. It brings together investigators from major cohorts to enable pooled analyses, harmonization of exposure and outcome data, and multi-cohort investigations across institutions such as Harvard University, National Institutes of Health, Mayo Clinic, Johns Hopkins University, and Stanford University. The Consortium facilitates large-scale projects linking biorepositories, epidemiologic methods, and statistical expertise drawn from centers like Fred Hutchinson Cancer Research Center, University of Washington, Columbia University, University of California, Los Angeles, and University of Oxford.

Overview

The Consortium operates as a federated collaboration among prospective cohort studies including landmark cohorts from Nurses' Health Study, Health Professionals Follow-up Study, Framingham Heart Study, Women's Health Initiative, and European Prospective Investigation into Cancer and Nutrition. Its mission aligns with initiatives at Centers for Disease Control and Prevention, American Cancer Society, Wellcome Trust, Bill & Melinda Gates Foundation, and other funders to support pooled analyses of rare cancers, gene–environment interactions, biomarker validation, and survivorship outcomes. Participants have drawn on expertise from disciplines represented at Harvard T.H. Chan School of Public Health, Yale School of Public Health, Karolinska Institutet, McGill University, and University of Toronto.

The Consortium was established in the late 1990s following discussions among investigators at meetings hosted by National Cancer Institute leadership and events such as the annual American Association for Cancer Research conference and symposia convened by International Agency for Research on Cancer. Early conveners included scientists affiliated with Brigham and Women's Hospital, Dana–Farber Cancer Institute, Moffitt Cancer Center, H. Lee Moffitt Cancer Center, and Roswell Park Comprehensive Cancer Center. Formation responded to growing recognition from reports by panels at Institute of Medicine and working groups at World Health Organization that pooled cohort analyses could address statistical power limitations identified in cohorts like Physicians' Health Study and Women's Health Study.

Membership comprises cohort principal investigators and institutional leaders from cohorts such as PLCO Cancer Screening Trial, European Prospective Investigation into Cancer and Nutrition, Nurses' Health Study II, Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial, and population cohorts coordinated from sites including Kaiser Permanente, University of California, San Francisco, University of Pittsburgh, University of Minnesota, and University of Michigan. The organizational structure includes steering committees, working groups, and protocol committees patterned after governance models used at National Institutes of Health consortia and cooperative groups such as Children's Oncology Group. Collaborative platforms mirror data harmonization efforts led by consortia associated with Human Genome Project institutions and bioresource networks like UK Biobank.

Research activities emphasize pooled epidemiologic analyses, nested case–control studies, biomarker discovery, and molecular epidemiology investigations. Major projects have investigated associations found in cohorts such as Nurses' Health Study and Health Professionals Follow-up Study of dietary exposures, smoking, and pharmaceutical agents with cancer endpoints evaluated in pooled analyses akin to work from EPIC investigators and meta-analyses published in journals that feature studies from New England Journal of Medicine, Journal of the American Medical Association, Lancet Oncology, Cancer Epidemiology, Biomarkers & Prevention, and International Journal of Epidemiology. Key topics include gene–environment interaction studies leveraging resources and expertise from Broad Institute, Wellcome Sanger Institute, Cancer Genome Atlas, and genotyping centers at Mayo Clinic and Johns Hopkins University. Collaborative projects have addressed rare cancers examined alongside registries such as Surveillance, Epidemiology, and End Results Program and trials from Children's Oncology Group.

Governance is overseen by committees drawing membership from institutions including National Cancer Institute, National Institutes of Health, Harvard University, Fred Hutchinson Cancer Research Center, and international partners such as Institut Pasteur and German Cancer Research Center. Funding mechanisms have included grants and cooperative agreements administered through National Cancer Institute program offices, investigator-initiated grants from National Institutes of Health, and supplemental funding from philanthropic organizations like American Cancer Society and foundations such as Robert Wood Johnson Foundation. Collaborative projects have also received resources via international funders including European Research Council and national research councils at universities like University of Tokyo.

The Consortium has enabled high-impact pooled analyses that clarified risk factors and biomarkers for multiple cancers, influenced screening recommendations debated in forums like U.S. Preventive Services Task Force, and informed guidelines promulgated by organizations such as American Cancer Society and European Society for Medical Oncology. Outputs include methodological advances in harmonization comparable to standards developed at International Agency for Research on Cancer, contributions to meta-analytic evidence synthesized by groups including Cochrane Collaboration, and training of investigators who have moved to leadership roles at Harvard T.H. Chan School of Public Health, Johns Hopkins Bloomberg School of Public Health, University of California, Berkeley, and Yale School of Medicine. The Consortium's pooled resources have supported translational research connecting epidemiology with molecular oncology efforts like those at Memorial Sloan Kettering Cancer Center and Dana–Farber Cancer Institute, enhancing understanding of carcinogenesis, prevention strategies, and survivorship care.

Category:Cancer epidemiology